32 related articles for article (PubMed ID: 29755114)
1. 3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis.
Mu M; Zhang Q; Zhao C; Li X; Chen Z; Sun X; Yu J
Cancer Gene Ther; 2023 Oct; 30(10):1414-1425. PubMed ID: 37558749
[TBL] [Abstract][Full Text] [Related]
2. MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.
Morimoto Y; Yamashita N; Hirose H; Fushimi A; Haratake N; Daimon T; Bhattacharya A; Ahmad R; Suzuki Y; Takahashi H; Kufe DW
Cancer Lett; 2023 Apr; 559():216116. PubMed ID: 36878307
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the new tyrphostin briva against BRAF
Saleh K; Al Sakhen M; Kanaan S; Yasin S; Höpfner M; Tahtamouni L; Biersack B
Invest New Drugs; 2023 Dec; 41(6):791-801. PubMed ID: 37870738
[TBL] [Abstract][Full Text] [Related]
4. KZ02 enhances the radiosensitivity of BRAF-mutated CRC in vitro and in vivo.
Guo Y; Li X; Yuan R; Ren J; Huang Y; Yu Y; Tian H
Eur J Pharmacol; 2023 Nov; 959():176060. PubMed ID: 37775019
[TBL] [Abstract][Full Text] [Related]
5. Assessing the Therapeutic Impacts of HAMLET and FOLFOX on BRAF-Mutated Colorectal Cancer: A Study of Cancer Cell Survival and Mitochondrial Dynamics In Vitro and Ex Vivo.
Žilinskas J; Stukas D; Jasukaitienė A; Žievytė I; Balion Z; Šapauskienė J; Banienė R; Paužas H; Lizdenis P; Čėsna V; Dambrauskas Ž; Gulbinas A; Tamelis A
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256402
[No Abstract] [Full Text] [Related]
6. Additive Cytotoxic and Colony-Formation Inhibitory Effects of Aspirin and Metformin on
Gonçalves J; Pinto S; Carmo F; Silva C; Andrade N; Martel F
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791419
[TBL] [Abstract][Full Text] [Related]
7. The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells.
Chen Y; Sang Y; Li S; Xue J; Chen M; Hong S; Lv W; Sehgal K; Xiao H; Liu R
Transl Oncol; 2024 Jul; 45():101991. PubMed ID: 38728872
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-induced ALDH3A1 promotes the proliferation of non-small-cell lung cancer by regulating energy metabolism reprogramming.
Chen Y; Yan H; Yan L; Wang X; Che X; Hou K; Yang Y; Li X; Li Y; Zhang Y; Hu X
Cell Death Dis; 2023 Sep; 14(9):617. PubMed ID: 37730658
[TBL] [Abstract][Full Text] [Related]
9. SPOP inhibits BRAF-dependent tumorigenesis through promoting non-degradative ubiquitination of BRAF.
Feng K; Shi Q; Jiao D; Chen Y; Yang W; Su K; Wang Y; Huang Y; Zhang P; Li Y; Wang C
Cell Biosci; 2022 Dec; 12(1):211. PubMed ID: 36585710
[TBL] [Abstract][Full Text] [Related]
10. Discovery of BRAF/HDAC Dual Inhibitors Suppressing Proliferation of Human Colorectal Cancer Cells.
Li Y; Huang Y; Cheng H; Xu F; Qi R; Dai B; Yang Y; Tu Z; Peng L; Zhang Z
Front Chem; 2022; 10():910353. PubMed ID: 35936102
[TBL] [Abstract][Full Text] [Related]
11. Comparative Analysis and in vitro Experiments of Signatures and Prognostic Value of Immune Checkpoint Genes in Colorectal Cancer.
Ma R; Qu X; Che X; Yang B; Li C; Hou K; Guo T; Xiao J; Liu Y
Onco Targets Ther; 2021; 14():3517-3534. PubMed ID: 34103942
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28.
Zhang C; Fan Y; Che X; Zhang M; Li Z; Li C; Wang S; Wen T; Hou K; Shao X; Liu Y; Qu X
Front Oncol; 2020; 10():760. PubMed ID: 32528882
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of the COX2/PGE
Yoshitake R; Saeki K; Eto S; Shinada M; Nakano R; Sugiya H; Endo Y; Fujita N; Nishimura R; Nakagawa T
Sci Rep; 2020 May; 10(1):7826. PubMed ID: 32385388
[TBL] [Abstract][Full Text] [Related]
14. Sur-X, a novel peptide, kills colorectal cancer cells by targeting survivin-XIAP complex.
Fang W; Che X; Li G; Wang A; Wang Y; Shi X; Hou K; Zhang X; Qu X; Liu Y
J Exp Clin Cancer Res; 2020 May; 39(1):82. PubMed ID: 32381104
[TBL] [Abstract][Full Text] [Related]
15. AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status.
Ma R; Xu L; Qu X; Che X; Zhang Y; Fan Y; Li C; Guo T; Hou K; Hu X; Drew L; Shen M; Cheung T; Liu Y
Br J Cancer; 2018 May; 118(11):1453-1463. PubMed ID: 29755114
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
17. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L
Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524
[TBL] [Abstract][Full Text] [Related]
18. BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells.
Wu Z; Huang M; Gong Y; Lin C; Guo W
Acta Biochim Biophys Sin (Shanghai); 2018 Apr; 50(4):355-361. PubMed ID: 29534162
[TBL] [Abstract][Full Text] [Related]
19. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
